InterMune Tweaks Design for Confirmatory Esbriet IPF Study
By Jennifer Boggs
Friday, May 27, 2011
Executives of Brisbane, Calif.-based InterMune Inc. disclosed details for the upcoming confirmatory trial needed for U.S. approval of idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) and told analysts Thursday that they believe some fine-tuning to the trial design could help the drug finally clear the FDA.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.